Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25285775 | 0.98 | TBXAS1 (0.61) | TBXAS1EGLN3 | |
| SCHEMBL29956974 | 0.94 | TBXAS1 (0.67) | TBXAS1 | |
| SCHEMBL7345121 | 0.92 | TBXAS1 (0.70) | TBXAS1 | |
| SCHEMBL2001148 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL25239361 | 0.86 | TBXAS1 (0.54) | TBXAS1EGLN3ALDH1A1 | |
| SCHEMBL937596 | 0.80 | TBXAS1 (0.95) | TBXAS1PRKCI | |
| SCHEMBL9777196 | 0.80 | TBXAS1 (0.85) | TBXAS1EGLN3PRKCI | |
| SCHEMBL10650074 | 0.80 | TBXAS1 (0.63) | TBXAS1PRKCIALDH1A1 | |
| SCHEMBL27585595 | 0.80 | TBXAS1 (0.63) | TBXAS1PRKCI | |
| Formic Acid SCHEMBL2524896 | 0.79 | TBXAS1 (0.68) | TBXAS1EGLN3PRKCIALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-1199971-C | Quaternary ammonium compounds as tachykinin antagonists | PFIZER LTD (US) | 2005-05-04 | — | — | CN | disclosed |
| EP-1187847-B1 | STREPTOGRAMIN DERIVATIVES, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-12-03 | — | — | EP | disclosed |
| CN-1260795-A | quaternary ammonium compounds as tachykinin antagonists | PFIZER LTD (US) | 2000-07-19 | — | — | CN | disclosed |
| US-5985869-A | USEFUL AS VASODILATORS, HYPOTENSIVE AGENTS, WATER DIURETICS, PLATELET AGGLUTINATION INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-11-16 | — | — | US | disclosed |
| US-5753677-A | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1107146-A | A process for preparing a composition containing benzoheterocycles | OTSUKA PHARMA CO LTD (JP) | 1995-08-23 | — | — | CN | disclosed |
| CN-1027505-C | Process for preparing benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| CN-1051038-A | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1991-05-01 | — | — | CN | disclosed |
| EP-0111384-B1 | THIOKETAL SUBSTITUTED N-ALKYL IMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4489087-A | Spermicidal thioketal substituted N-alkyl imidazoles | SYNTEX (U.S.A.) INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0111384-A1 | Thioketal substituted N-alkyl imidazoles and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | TBXAS1 643/4885EGLN3 1992/4885PRKCI 2155/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | TBXAS1 643/4885EGLN3 1992/4885PRKCI 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.